The genes glutathione S-transferase M1 (GSTM1) (chromosome 1p13.3) and glutathione S-transferase T1 (GSTT1) (22q11.2) code for cytosolic enzymes glutathione S-transferase (GST)-u. and GST-8, respectively, which are involved in phase 2 metabolism. Both genes may be deleted. There is geographic and ethnic variation in genotype frequencies for both genes. In developed countries, colorectal cancer is the second most common cancer. Colorectal cancer has been inconsistently associated with polycyclic aromatic hydrocarbons in diet and tobacco. Because GST enzymes are involved in polycyclic aromatic hydrocarbon metabolism, it has been postulated that genotype may modify colorectal cancer risk associated with polycyclic aromatic hydrocarbon exposure. No consistent associations between GSTM1 or GSTT1 genotype and colorectal cancer have been observed. However, most studies have methodological limitations. Few have investigated gene-environment interactions. No interactions between GSTM1 or GSTT1 genotype and smoking and colorectal cancer risk have been reported. One polyp study suggests an interaction between GSTM1 genotype and smoking. Two studies suggest increased disease risk in subjects with high meat intake and GST nonnull genotype, contrary to the underlying hypothesis. One study suggests a strong inverse relation between colorectal adenomas and broccoli consumption, particularly in subjects who are GSTM1 null. These finding require confirmation. Methods for determining GSTM1 and GSTT1 genotype are well established. Population testing is not currently justified. Am J Epidemiol 2000; 151:7-32. colorectal neoplasms; epidemiology; glutathione transferase; GSTM1; GSTT1
GST substrates are xenobiotics or products of oxidative stress, including some environmental carcinogens (1) . In particular, the enzymes detoxify the carcinogenic polycyclic aromatic hydrocarbons present in diet and tobacco smoke (3) . They also conjugate isothiocyanates, which are potent inducers of enzymes that detoxify environmental mutagens (4) , to glutathione, thereby diverting the isothiocyanates from the enzyme induction pathway to excretion (5) . It has been postulated that the GST enzymes and the genes encoding these may be involved in susceptibility to cancer (6) .
The genes coding for the enzymes GST-(0. and GST-9 are polymorphic. There are three alleles at the GSTM1 locus, located on chromosome Ipl3.3: GSTM1 nulla deletion, GSTMla, and GSTMlb (6) . GSTMla and b differ by a substitution in one base pair. There is no evidence of functional differences between them (6). The GSTT1 locus is located on chromosome 22qll.2 and is, in some instances, deleted (6) . For both GSTM1 and GSTT1, the hypothesized consequence of the null genotype is reduced conjugation activity or no conjugation activity. Evidence is lacking on whether heterozygosity in either GSTM1 or GSTT1 affects gene function. Phase 2 metabolism of Reduced or no xenobiotics conjugation activity * The subfamilies GSTA and GSTP that code for the isoenzymes GST-a and GST-n also exist, but are not considered in this review.
t These two alleles differ by only one base pair. There is no evidence of functional differences between them.
GENE VARIANTS
We searched MEDLINE and EMBASE using the Medical Subjects Headings in Index Medicos heading "glutathione transferase" and the text words "GST' and "glutathione S-transferase" for papers published between 1993 and 1998. We also searched the Centers for Disease Control and Prevention Office of Genetics and Disease Prevention Medical Literature Search and reviewed reference lists in published articles. We identified relevant papers and critically appraised them. This section includes studies that reported genotype frequencies in a variety of groups of individuals who did not have cancer.
The frequency of individuals who are homozygous for the GSTM1 null genotype is summarized in table 2 , and those homozygous for the GSTTl null genotype are summarized in table 3 (8, 10, 11, 14, 29, 32, 35-37, 39, 47-49, 51-53, 55, 58, 59, 63, 65, 68, 73-75, 77, 78, 80-85) . Many of the series were control groups in case-control studies of cancer. However, few could be described as truly population based; therefore, selection or participation biases may account for some of the variation between studies. Some of the studies have small numbers of participants. It is not always easy to establish ethnicity, nor is it necessarily sufficient to simply categorize individuals as belonging to one of the major ethnic groups (86) ; this limits the generalizability from, for example, one "white" population to another.
GSTM1
In African populations, the frequency of the GSTM1 null genotype ranges from 23 to 48 percent; in Asian populations, from 33 to 63 percent; and in European populations, from 39 to 62 percent.
Published data from the Americas relate only to studies carried out in the United States; the range of reported frequencies is 23-62 percent. In African Americans and Blacks, the range is 23-41 percent, and in whites, it is 35-62 percent. In the two studies of subjects of Asian origin, the range was 32-53 percent, and in the three studies that included Hispanic/MexicanAmerican subjects, the range was 40-53 percent.
In two Australian series, the frequency is 51-54 percent. The highest frequencies have been reported in studies involving small numbers of subjects from parts of the South Pacific-64-100 percent (13) . These studies differed from the others in that Southern blot analysis rather than polymerase chain reaction methodology was used.
GSTT1
The range of frequencies of the GSTTl null genotype is 16-64 percent in Asia, with frequencies of 44 percent or higher being reported in China, Japan, Korea, and the Singapore Chinese. Thus, in some Asian populations, it has been suggested that the frequency of GSTTl null deletions is similar to that of GSTM1 null. However, in African, African-American, and white populations, the frequencies of GSTTl null are lower than those of GSTM1 null. The range of frequencies in three African series is 15-26 percent, and in Europe, it is 10-21 percent. As was the case for GSTM1, data from the Americas relate only to the United States, where the range of frequencies is 10-36 percent. In whites, the range is 15-27 percent; in African Americans and Blacks, it is 22-29 percent; and in Mexican Americans, based on two studies, it is 10-12 percent. No data on Asian subjects in the United States are available. In three groups in Australia, the frequency of GSTTl null ranged from 9 to 19 percent.
Concordance between genotype and phenotype
Individuals lacking GST-p. or GST-8 activity can be identified by using phenotypic assays that classify individuals as active or inactive on the basis of a bimodal distribution. Use of polymerase chain reaction methodology indicates the presence or absence of the GSTM1 or GSTTl alleles. Several studies have investigated concordance between genotype and phenotype; this can be a means of determining whether the appro-Glutathione S-Transferase and Colorectal Cancer 9 priate section of DNA coding for the particular phenotype has been identified.
Four studies in Europe and one in the United States have demonstrated concordances between GSTM1 genotype and GST-u, phenotype of 94 percent or greater (26, 33, (87) (88) (89) . However, in one study in which genotype and phenotypic status were compared in 63 healthy Zimbabwean volunteers, concordance was lower, at 84 percent (90) . This may have been due to the presence of 1) other mutations that affect protein expression, 2) compounds in the diet that may affect protein levels, or 3) mutations in the regions of the gene that bind to the primers during the polymerase chain reactions but that do not affect enzyme activity (90) . Genotyping methods developed in populations of European origin may slightly underestimate the proportion of African populations with the GSTM1 null genotype (90) .
In two small studies (82, 91) and one larger one (83) in northern European populations, concordance between GSTT1 genotype and conjugator status (phenotype) in excess of 95 percent was found.
DISEASE
Worldwide in 1996, there were an estimated 875,000 new cases of colorectal cancer (92) . There is substantial geographic variation in incidence (figure 1) (93) . Epidemiologic evidence suggests that much of the geographic variation reflects variations in environmental or lifestyle exposures, perhaps acting with variations in genetic factors. In developed countries, colorectal cancer is the second most common cancer, and in developing countries, it ranks sixth most common in men and fifth in women (94) . In developed countries, the age-standardized rates (30-^47 per 100,000 in men and 24-31 per 100,000 in women) are typically about four times higher than those in some developing countries (rates below 10 per 100,000 for both sexes) (93) . The incidence of colorectal cancer is rising in most populations (95) .
In most populations, cancer of the colon is more common than that of the rectum (93) . The male:female ratio for colon cancer is approximately unity, and that for rectal cancer is 1.5 or greater (93) . The incidence of colorectal cancer increases with age (93) .
After exclusion of familial adenomatous polyposis or hereditary nonpolyposis colorectal cancer, the risks of colorectal cancer to first-degree relatives of index patients with the disease is about twice that of the general population (96, 97) . The genetic basis of this familial aggregation has not yet been characterized.
Colorectal adenomatous polyps are thought to be precursors of colorectal cancer. While there is no direct evidence in support of the adenoma-carcinoma sequence, there is considerable indirect evidence from a range of epidemiologic, histopathologic, and molecular genetic studies (98) .
Exposure of meats to pyrolysis temperatures produces heterocyclic amines and polycyclic aromatic hydrocarbons (99, 100) . The World Cancer Research Fund/American Institute of Cancer Research panel recently concluded that consumption of red meat "probably" increases and intake of heavily cooked meats "possibly" increases the risk of colorectal cancer (101) . In some studies, elevated risks of colorectal cancer have been associated with consumption of broiled or grilled meats and browning of the meat surface (102, 103) . In a recent study, an increase in risk associated with higher levels of both a white meat and an overall meat mutagen index in men was found (104) . However, in other studies, no association with consumption of broiled or grilled meats or browning of the meat surface was observed (105, 106) .
High intake of alcohol may be associated with increased risk of colorectal lesions (98) . With regard to dietary factors that may be protective, the World Cancer Research Fund/American Institute of Cancer Research panel concluded that there is "convincing" evidence that the consumption of vegetables decreases the risk of colon cancer and "possible" evidence that the consumption of nonstarch polysaccharides/fiber, starch, and carotenoids does so (101) . In eight of 12 studies of colon cancer and all five studies of rectal cancer, high levels of consumption of cruciferous vegetables were associated with decreased risks (101) . Cruciferous vegetables may have anticarcinogenic properties, since they contain isothiocyanates that induce enzymes that detoxify environmental mutagens (4, 5) .
In addition to diet, the other major environmental source of exposure to polycyclic aromatic hydrocarbons is tobacco smoke. Most studies show a positive association between smoking and colorectal adenomas, but the association between smoking and colorectal cancer is less clear (107) . However, in four recent, large cohort studies, smoking has been associated with colorectal cancer after a long latent period (108) (109) (110) (111) .
There is consistent evidence from observational studies that higher levels of physical activity are associated with a reduced risk of colon cancer (112) .
While the evidence from observational studies suggests that regular use of aspirin or other nonsteroidal, anti-inflammatory drugs reduces the risk of colorectal cancer, no protective effect was found in the intervention trial in which US male physicians were given 325 mg aspirin on alternate days or a placebo for, on average, 5 years (113). 
ASSOCIATIONS
The studies appraised in this section were identified by using the search strategy described earlier, with the addition of Medical Subject Headings in Index Medicus headings and text words relevant to colorectal cancer or polyps.
GSTM1 and colorectal cancer
The eight available case-control studies of GSTM1 and colorectal cancer (14, 23, 49, 54, 58, 69, 77, 78) and one of colorectal adenomas (114) are summarized in table 4 and discussed below in order of publication. In four of the studies (14, 58, 69, 114) , exposure to environmental and lifestyle factors was assessed; this is discussed in the Interactions section of this paper.
The results of the colorectal cancer studies are inconsistent: Three suggested no association (49, 58, 77) , three suggested a slightly lower risk in those with the GSTM1 null genotype (23, 69, 78) , and two, an increased risk associated with this genotype (14, 54) . The study of colorectal adenomas suggests a slightly lower risk in those with GSTM1 null genotype (114) .
In the first reported study of colorectal cancer and GSTM1, Zhong et al. (54) found a significantly raised relative risk associated with the GSTM1 null genotype among 196 cases from an Edinburgh hospital and 225 controls from Sheffield, Edinburgh, and Potters Bar (relative risk (RR) = 1.8, 95 percent confidence interval (CI): 1.2,2.6). This is the only study in which a statistically significant association was observed. The risk was especially elevated for those with a proximal tumor (RR = 3.4, 95 percent CI: 1.9, 6.0).
Chenevix-Trench et al. (78) investigated 132 patients with colorectal adenocarcinoma and 200 controls in Australia. Of the controls, 100 were "unselected," and no further information on them was presented; the remainder were geriatric patients without cancer or a family history of cancer. The relative risk of colorectal cancer associated with the GSTM1 null genotype was 0.9 (95 percent CI: 0.6, 1.4). When the analysis was restricted to cases with a proximal tumor, the RR was also 0.9 (95 percent CI: 0.4, 1.8). The proportions of cases aged less than 70 and over 70 years who were GSTM1 null were not significantly different. The authors acknowledge that their study had fewer cases, a smaller proportion of cases with proximal tumors, and a higher proportion of controls who carried the null genotype than did the study by Zhong et al. (54) , and, hence, there may have been inadequate statistical power to detect a relation of the type observed in the earlier study.
In a Japanese study of 103 consecutive colorectal adenocarcinoma patients and 126 subjects with no gastrointestinal symptoms or current or previous diagnosis of cancer who visited local medical clinics for regular medical checkups, an RR of 1.5 (95 percent CI: 0.9,2.6) associated with the GSTM1 null genotype was observed (14) . For proximal cases, the RR was 1.2 (95 percent CI: 0.6, 2.3), and for distal cases, it was 2.0 (95 percent CI: 1.0,3.9).
In another study in the United Kingdom of 252 colorectal cancer patients and 577 patients without malignancy or inflammatory pathologies recruited through the same hospital, Deakin et al. (49) RR of colon cancer associated with the GSTMl null genotype for men and women combined was 0.9 (95 percent CI: 0.8, 1.1). When the analysis was stratified by age (<67 years, >67 years), the relative risks were not substantially different. When proximal and distal tumors were considered separately, the crude RRs for both genders combined associated with the GSTMl null genotype were 1.0 (95 percent CI: 0.8, 1.1) and 0.9 (95 percent CI: 0.8, 1.1) respectively. In the one study of colorectal adenomatous polyps, from the United States (114), 446 cases were matched with 488 controls who did not have colorectal adenomas on sex, age, date of sigmoidoscopy, and center. The RR associated with the GSTMl null genotype was 0.9 (95 percent CI: 0.7, 1.1) (adjusted for the matching factors). When the analysis was stratified by ethnic group, the RR for whites was 1.0 (95 percent CI: 0.7, 1.4), that for Hispanics (not Blacks) was 0.8 (95 percent CI: 0.4, 1.7), that for Blacks was 0.6 (95 percent CI: 0.3, 1.4), and that for Asians and Pacific Islanders was 0.4 (95 percent CI: 0.2, 1.1). Cases and controls were identified after sigmoidoscopy. Only the left colon is accessible to sigmoidoscopy, so it is possible that some controls harbored tumors in the rest of their colon. The effect of this would be to bias the relative risks toward the null.
GSTT1 and colorectal cancer
Six of the studies described above also reported GSTT1 genotype (table 5) (14, 23, 49, 58, 77, 78) . Two assessed exposure and are discussed in the Interactions section of this paper (14, 58) .
The results of these studies are inconsistent. In two studies (49, 77) , the GSTT1 null genotype was associated with a statistically significant increase in the risk of colorectal cancer, while in the other four, no noteworthy associations were apparent.
Chenevix-Trench et al. (78) reported an RR for colorectal cancer of 0.9 (95 percent CI: 0.4, 1.7) associated with the GSTT1 null genotype when the unselected and the geriatric controls were considered together. However, when the analysis was repeated using the different control groups separately, the RRs were 0. (104) provides further results for the same study population. i The result presented here Is for men and women combined and Is unadjusted. However, the authors present the relative risk for men (RR = 1.0, 95 percent Cl; 0.8, 1.2) and women (RR -0.9, 95 percent Cl: 0.7, 1.1) separately, adjusted for age, energy Intake, body mass Index, long-term physical activity, dietary fiber, and usual number of cigarettes smoked.
§ The paper by Un et al. (5) provides further results for the same study population. This more recent paper has an additional 13 cases and 19 controls. Katoh et al. (14) found an RR of 1.2 (95 percent CI: 0.7, 2.0) for colorectal cancer, and Butler et al. (77) reported an RR of 3.4 (95 percent CI: 2.1, 5.4) associated with the GSTTl null genotype. Neither of these studies presented relative risks in relation to tumor subsite.
Gertig et al. (58) reported an RR of colorectal cancer associated with the GSTTl null genotype of 0.8 (95 percent CI: 0.5, 1.2), adjusted for body mass index, physical activity, and alcohol use. For proximal tumors, the adjusted RR was 0.9 (95 percent CI: 0.5, 1.7), and for distal tumors, it was 0.6 (95 percent CI: 0.3, 1.2). In men aged less than 60 years, the RR associated with GSTTl null genotype was 0.5 (95 percent CI: 0.2, 1.0), and in those aged 60 years or older, it was 0.9 (95 percent CI: 0.5, 1.7). It is not clear whether the age-stratified relative risks were adjusted.
Lee et al. (23) stated that the frequency of the GSTTl null genotype was similar in both cases and controls and that tumor histology had no effect on the frequency of the null genotype. However, insufficient information was presented for a relative risk to be calculated.
Comment on the studies on GSTM1 and GSTT1 and colorectal cancer
It is difficult to assess how far selection and participation biases may account for the inconsistencies in the results. Most studies involved hospital-based case series, and most of the control groups were not population based. This has implications for the generaliz-ability of the study results. The potential problems of selecting controls who do not represent the population from which cases arose is demonstrated by the divergence in relative risks obtained for the GSTTl null genotype when the different control groups were analyzed in the study by Chenevix-Trench et al. (78) . Most of the studies were not large; five included fewer than 250 cases. The smaller studies are likely to have limited statistical power, particularly for subgroup analyses. Two of the studies were undertaken in Asian populations; the others were in predominantly white populations. There is little information available for other ethnic groups. It is unclear whether any of the established risk factors for colorectal cancer are associated with the GSTM1 or GSTTl genotype. The studies made little attempt to adjust for potential confounders.
The findings of these studies require confirmation in other populations.
GSTM1 and other cancers
In a recent review, Rebbeck (6) suggests that there is evidence from case-control studies that GSTM1 is involved in the etiology of both lung and bladder cancers, although not all studies have shown this. While some studies of other cancer sites have shown an association with GSTM1, these findings have not been confirmed.
GSTT1 and other cancers
There have been fewer case-control studies of GSTTl. Statistically significant associations have been reported for astrocytoma, meningioma, and myelodysplasia, but these have not been confirmed (6) .
INTERACTIONS
Because the GST enzymes have detoxifying activity, it would be expected that, rather than affecting the risk of cancer per se, they would modify risk in relation to exposure to potential carcinogens. The enzymes play a major role in the detoxification of polycyclic aromatic hydrocarbons found in tobacco smoke and in cooked and processed meats. In four studies of colorectal lesions and GSTM1 (14, 58, 69, 114) and two of GSTTl (14, 58) , exposure to tobacco smoke was considered. Meat consumption was considered in relation to GSTM1 in two studies (58, 104) and in relation to GSTTl in one (58) . Consumption of broccoli, the richest source of isothiocyanates that induce enzymes that detoxify environmental mutagens, was considered in a study of GSTM1 and colorectal adenomas (5) . Three studies have considered GST gene-gene interactions and colorectal cancer (23, 58, 69) .
The limited statistical power of small studies to detect associations between genotype and disease is particularly important with regard to effect modification. To give adequate statistical power to detect a multiplicative interaction, very large sample sizes (in some circumstances, thousands of cases) may be required (115) .
GSTM1 and smoking
Little evidence of interaction between GSTM1 genotype, tobacco exposure, and colorectal cancer was found in the three studies (14, 58, 69) . However, the one polyp study (114) suggests that the GSTM1 genotype may modify the association between smoking and disease.
Lin et al. (114) report the effect of cigarette smoking and GSTM1 on adenoma risk. With a reference group of subjects who were never smokers and were GSTM1 positive, significantly increased adenoma risk was seen both in current smokers who were GSTM1 positive (RR = 1.7, 95 percent CI: 1.0, 2.9) and in current smokers who were GSTM1 null (RR = 2.1, 95 percent CI: 1.1, 3.8). When this analysis was restricted to adenomas greater than 1 cm in size, the RRs were 1.3 (95 percent CI: 0.6, 2.9) and 2.5 (95 percent CI: 1.1, 5.5).
Katoh et al. (14) reported that GSTM1 did not influence risk differently in subjects classified by smoking status (smoker or nonsmoker) or extent of tobacco exposure (pack-years).
Gertig et al. (58) investigated the joint effect of GSTM1 and cigarette smoking status at entry into the Physicians' Health Study on subsequent risk of colorectal cancer. The RR associated with the GSTM1 null genotype was 1.1 (95 percent CI: 0.6, 2.1) in never smokers, 1.0 (95 percent CI: 0.6, 1.6) in past smokers, and 1.2 (95 percent CI: 0.3, 4.2) in current smokers. There was no significant interaction between packyears of smoking at baseline and GSTM1 genotype.
In the study of Slattery et al. (69) , those who smoked more than one pack per day were at approximately 40 percent increased risk of colon cancer. No interaction was observed in either men or women between GSTM1 genotype and any of the following categories of tobacco exposure: smoking status, usual number of cigarettes smoked per day, pack-years of cigarettes smoked, age started smoking cigarettes, and years since stopping smoking cigarettes.
GSTT1 and smoking
Katoh et al. (14) reported that smoking had no effect on the risk associated with GSTTl genotypes. 
GSTM1 and meat intake
In the study by Gertig et al. (58) , men who were homozygous for GSTM1 null who consumed more than one serving of red meat per day were at slightly lower risk compared with men who were not homozygous for GSTM1 null who consumed less than 0.5 servings per day (RR = 0.8, 95 percent CI: 0.4, 2.0).
Kampmann et al. (104) reported associations between GSTM1 genotype and various measures of meat consumption in the subjects investigated by Slattery et al. (69) . There was no evidence that GSTM1 genotype modified the relative risks associated with amount of 1) red meat, 2) processed meat, or 3) poultry consumed; 4) frequency of fried, broiled, baked, or barbecued red meat; 5) preferred "doneness" of red meat; 6) frequency of use of red meat drippings; 7) frequency of use of white meat drippings; or 8) red meat mutagen index. GSTM1 genotype modified risks associated with frequency of consumption of fried, broiled, baked, or barbecued white meat; white meat mutagen index; and total meat mutagen index. Unexpectedly, the strongest positive associations were observed among those who were GSTM1 positive.
GSTT1 and meat intake
In the Physicians' Health Study (58) , men who were GSTT1 null homozygous and who consumed more than one serving of red meat daily had a lower risk compared with men who were GSTT1 nonnull and who consumed less than 0.5 servings daily (RR = 0.4, 95 percent CI: 0.1, 1.4).
GSTM1 and isothlocyanates
Lin et al. (5) postulated that a cancer preventive effect of broccoli would be stronger in GSTM1 null individuals and investigated this in the subjects studied earlier by Lin et al. (114) . Compared with subjects in the lowest quartile of broccoli intake who were GSTM1 null, those in the highest intake quartile who were null had an RR of 0.36 (95 percent CI: 0.19,0.68), and those in the highest intake quartile who were GSTM1 positive had an RR of 0.74 (95 percent CI: 0.40, 0.99); this interaction was statistically significant (p -0.01).
GSTM1, GSTT1, and other genes
In the Physicians' Health Study (58) , there was no increased risk of colorectal cancer in men who were homozygous null for both GSTM1 and GSTT1 compared with those who were homozygous positive for both GSTM1 and GSTT1. By contrast, Lee et al. (23) reported that 35 percent of cases with right-side tumors were GSTM1 null and GSTT1 positive compared with 22 percent of the control series.
Slattery et al. (69) considered the possibility of an interaction between GSTM1 and N-acetyltransferase 2 (NAT2) genotypes. There was a suggestion that women with the combined NAT2 intermediate/rapid and GSTM1 -positive genotypes were at increased risk compared with those with NAT2 s\ow/GSTMl -positive genotypes (unadjusted RR = 1.5, 95 percent CI: 1.11, 2.05). This was restricted to women older than age 67 years who had proximal tumors. However, the association was weaker and was not statistically significant in men (unadjusted RR -1.2, 95 percent CI: 0.89, 1.51). There was no strong evidence of any interaction between NAT2, GSTM1, and smoking in either men or women.
LABORATORY TESTS
For classification of an individual as GSTM1 null or nonnull (or GSTT1 null or nonnull), the genotyping procedure detects either the absence or the presence of the GSTM1 (or the GSTT1) gene. Therefore, after the gene has been amplified by polymerase chain reaction methodology, the product need only be visualized. This method cannot, however, distinguish between the GSTM1 *A and GSTM1 *B alleles. For this, a restriction digest must be undertaken. This cleaves the DNA into fragments of characteristic sizes, and the different combinations of these fragments correspond to specific alleles.
To ensure that a polymerase chain reaction occurred, a number of quality control procedures should undertaken. Additional "control" primers should be added. These amplify another region of DNA (one that is thought never to be deleted) to confirm that amplification has worked in null individuals. Along with the samples being amplified, a positive and a negative control should be run. The positive control is a sample of DNA known to contain the gene (i.e., not null); both the band representing the gene in question and the control band should be visible for the genotyping to be validated. The negative control allows a check for contamination to be made; if amplification is seen in this control, the samples run at the same time should not be genotyped. In general, the studies present little information on the proportion of subjects for whom the genotype could be determined or on reproducibility of genotyping.
Much of the polymerase chain reaction work on genotyping has used DNA from blood; however, work involving DNA from mouthwash samples is now being undertaken (116) . This development makes polymerase chain reaction methodology even more appropriate for researchers undertaking molecular epidemiology studies, since it enables subjects to be genotyped without the need for invasive sampling.
GSTM1
In two of the nine studies of GSTM1 and colorectal lesions, no details of the primers used are given (23, 77) . Three studies (58, 78, 114) use the same primers to amplify the GSTM1 gene, although they reference different papers for these methods (64, 89, 117) . The primer 5'-CTGCCCTACTTGATTGATGGG-3' anneals to the 5' region of exon 4, and the primer 5'-CTG-GATTGTAGCAGATCATGC-3' anneals to the 3' region of exon 5. They amplify a 273 base-pair product, but use slightly different amplification cycles. Katoh et al. (14) 5'-ATCTTCTCCTCTTCTGTCTC-3', and P3 5'-TTCTGGATTGTAGCAGATCA-3') are combined in a single polymerase chain reaction. Primers PI and P3 amplify a 230 base-pair product specific to GSTM1; primers PI and P2 anneal to either GSTMJ or GSTM4 and amplify a 157 base-pair product, thereby acting as the control primers.
In another two studies, explicit mention is made of the use of control primers: Chenevix-Trench et al. (78) used primers for exon 1 of coagulation factor XHI, and Katoh et al. (14) used primers for fi-globin. In the methodology of Warwick et al. (84) , used by Deakin et al. (49) , [3- globin is again used as the control primer. In two studies (14, 58) , the use of positive and negative controls samples is reported.
GSTT1
In two of the six studies (23, 77) , no details on the methods used are given. In the other four (14, 49, 58, 78) , the genotyping methods outlined by Pemble et al. (91) were used. The primers used for amplification in this method are TTCCTTACTGGTCCTCACATCTC and TCACCGGATCATGGCCAGCA. In two studies, the use of control primers is described: ChenevixTrench et al. (78) used primers for glutathione 5-transferase PI, and Katoh et al. (14) used primers for p-globin. In two studies (14, 58) , the use of positive and negative controls samples is mentioned.
